{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:35:19Z","timestamp":1790638519081,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40487-022-00215-2","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T12:03:03Z","timestamp":1673870583000},"page":"111-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer"],"prefix":"10.1007","volume":"11","author":[{"given":"Sandrine","family":"Barbier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Reyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Meitour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreanne","family":"Lortie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Hillairet","family":"de Boisferon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Chaumeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Espirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Klinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunthathi","family":"Thiagalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Lezmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Meyer-Losic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"215_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394\u2013424.","journal-title":"Cancer J Clin"},{"key":"215_CR2","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187\u201391.","journal-title":"Cancer Res"},{"key":"215_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/IJN.S88084","volume":"11","author":"AH Ko","year":"2016","unstructured":"Ko AH. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine. 2016;11:1225\u201335.","journal-title":"Int J Nanomedicine"},{"key":"215_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1634\/theoncologist.2-6-359","volume":"2","author":"RB Ewesuedo","year":"1997","unstructured":"Ewesuedo RB, Ratain MJ. Topoisomerase I inhibitors. Oncologist. 1997;2:359\u201364.","journal-title":"Oncologist"},{"key":"215_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104398","volume":"148","author":"C Bailly","year":"2019","unstructured":"Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148: 104398.","journal-title":"Pharmacol Res"},{"key":"215_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01364:JCO2001364","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.20.01364:JCO2001364.","journal-title":"J Clin Oncol"},{"key":"215_CR7","unstructured":"ESMO Guidelines Committee, eUpdate\u2014Cancer of the pancreas treatment recommendations https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/gastrointestinal-cancers\/pancreatic-cancer. Accessed 7 July."},{"key":"215_CR8","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1200\/JCO.19.00946","volume":"37","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37:2082\u20138.","journal-title":"J Clin Oncol."},{"key":"215_CR9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"215_CR10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","volume":"57","author":"FM De Man","year":"2018","unstructured":"De Man FM, Goey AKL, Van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229\u201354.","journal-title":"Clin Pharmacokinet"},{"key":"215_CR11","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1158\/1078-0432.CCR-08-0736","volume":"14","author":"JH Baker","year":"2008","unstructured":"Baker JH, Lam J, Kyle AH, et al. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res. 2008;14:7260\u201371.","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"215_CR12","doi-asserted-by":"publisher","first-page":"e16205","DOI":"10.1200\/JCO.2018.36.15_suppl.e16205","volume":"36","author":"SG Klinz","year":"2018","unstructured":"Klinz SG, Leonard SC, Paz N, et al. DNA damage with liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts: multimodal analysis of deposition characteristics. J Clin Oncol. 2018;36(Suppl):e16205.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"215_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1200\/JCO.2018.36.4_suppl.335","volume":"36","author":"SC Leonard","year":"2018","unstructured":"Leonard SC, Paz N, Klinz SG, et al. Deposition characteristics and resulting DNA damage patterns of liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts. J Clin Oncol. 2018;36(Suppl):335.","journal-title":"J Clin Oncol"},{"key":"215_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/(SICI)1097-0215(19971210)73:6<891::AID-IJC22>3.0.CO;2-6","volume":"73","author":"WJ Jansen","year":"1997","unstructured":"Jansen WJ, Kolfschoten GM, Erkelens CA, et al. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Int J Cancer. 1997;73:891\u20136.","journal-title":"Int J Cancer"},{"key":"215_CR15","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","volume":"66","author":"DC Drummond","year":"2006","unstructured":"Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271\u20137.","journal-title":"Cancer Res"},{"key":"215_CR16","unstructured":"Ipsen Biopharmaceuticals, Inc. Prescribing Information, ONIVYDE\u00ae (irinotecan liposome injection). US Food and Drug Administration https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/sites\/9\/2019\/01\/21083350\/ONIVYDE_USPI.pdf. Accessed 29 June 2021."},{"key":"215_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2021.03.028","volume":"151","author":"ZA Wainberg","year":"2021","unstructured":"Wainberg ZA, Bekaii-Saab T, Boland PM, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I\/II study. Eur J Cancer. 2021;151:14\u201324.","journal-title":"Eur J Cancer"},{"key":"215_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","volume":"91","author":"H Maeda","year":"2015","unstructured":"Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3\u20136.","journal-title":"Adv Drug Deliv Rev"},{"key":"215_CR19","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","volume":"74","author":"AV Kalra","year":"2014","unstructured":"Kalra AV, Kim J, Klinz SG, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74:7003\u201313.","journal-title":"Cancer Res"},{"key":"215_CR20","unstructured":"Surveillance, Epidemiology, and End Results Program\u2014Cancer Stat Facts: Pancreatic Cancer https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Accessed 28 June 2021."},{"key":"215_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrd4090","volume":"12","author":"J Arrowsmith","year":"2013","unstructured":"Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011\u20132012. Nat Rev Drug Discov. 2013;12:569.","journal-title":"Nat Rev Drug Discov"},{"key":"215_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00439-011-1010-0","volume":"130","author":"AV Biankin","year":"2011","unstructured":"Biankin AV, Hudson TJ. Somatic variation and cancer: therapies lost in the mix. Hum Genet. 2011;130:79\u201391.","journal-title":"Hum Genet"},{"key":"215_CR23","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.","journal-title":"Nat Commun."},{"key":"215_CR24","first-page":"3","volume":"17","author":"C Xu","year":"2019","unstructured":"Xu C, Li X, Liu P, Li M, Luo F. Patient-derived xenograft mouse models: a high fidelity tool for individualized medicine. Oncol Lett. 2019;17:3\u201310.","journal-title":"Oncol Lett"},{"key":"215_CR25","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko E, Paz K, Ciznadija D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017;28:2595\u2013605.","journal-title":"Ann Oncol"},{"key":"215_CR26","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29:4548\u201354.","journal-title":"J Clin Oncol"},{"key":"215_CR27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998\u20131013.","journal-title":"Cancer Discov"},{"key":"215_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0167-4781(98)00143-2","volume":"1400","author":"J Thompson","year":"1998","unstructured":"Thompson J, Stewart CF, Houghton PJ. Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta. 1998;1400:301\u201319.","journal-title":"Biochim Biophys Acta"},{"key":"215_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1385\/1-59259-866-8:127","volume-title":"Camptothecins in cancer therapy. Cancer Drug Discovery and Development","author":"AS Juvekar","year":"2005","unstructured":"Juvekar AS, Thompson J, Stewart CF, Hougton PJ. Preclinical models for evaluating topoisomerase I-targeted drugs. In: Adams VR, Burke TG, editors. Camptothecins in cancer therapy. Cancer Drug Discovery and Development. Totowa: Humana Press; 2005. p. 127\u201351."},{"key":"215_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11095-017-2278-0","volume":"35","author":"AS Mohammad","year":"2018","unstructured":"Mohammad AS, Griffith JI, Adkins CE, et al. Liposomal irinotecan accumulates in metastatic lesions, crosses the blood-tumor barrier (BTB), and prolongs survival in an experimental model of brain metastases of triple negative breast cancer. Pharm Res. 2018;35:31.","journal-title":"Pharm Res"},{"key":"215_CR31","first-page":"68","volume":"12","author":"ML Rothenberg","year":"1998","unstructured":"Rothenberg ML, Kuhn JG, Schaaf LJ, et al. Alternative dosing schedules for irinotecan. Oncology (Williston Park). 1998;12:68\u201371.","journal-title":"Oncology (Williston Park)"},{"key":"215_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00001813-199704000-00002","volume":"8","author":"J Thompson","year":"1997","unstructured":"Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs. 1997;8:313\u201322.","journal-title":"Anticancer Drugs"},{"key":"215_CR33","first-page":"32","volume":"7","author":"S Blaney","year":"2001","unstructured":"Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 2001;7:32\u20137.","journal-title":"Clin Cancer Res"},{"key":"215_CR34","first-page":"69","volume":"5","author":"CJ Gerrits","year":"1999","unstructured":"Gerrits CJ, Schellens JH, Burris H, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res. 1999;5:69\u201375.","journal-title":"Clin Cancer Res"},{"key":"215_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF00686188","volume":"36","author":"PJ Houghton","year":"1995","unstructured":"Houghton PJ, Cheshire PJ, Hallman JD 2nd, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393\u2013403.","journal-title":"Cancer Chemother Pharmacol"},{"key":"215_CR36","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cpt.720","volume":"102","author":"BS Adiwijaya","year":"2017","unstructured":"Adiwijaya BS, Kim J, Lang I, et al. Population pharmacokinetics of liposomal irinotecan in patients with cancer. Clin Pharmacol Ther. 2017;102:997\u20131005.","journal-title":"Clin Pharmacol Ther"},{"key":"215_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-14-1882","volume":"21","author":"MH Kang","year":"2015","unstructured":"Kang MH, Wang J, Makena MR, et al. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing\u2019s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015;21:1139\u201350.","journal-title":"Clin Cancer Res"},{"key":"215_CR38","first-page":"2116","volume":"55","author":"F Goldwasser","year":"1995","unstructured":"Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 1995;55:2116\u201321.","journal-title":"Cancer Res"},{"key":"215_CR39","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41416-020-01199-4","volume":"124","author":"C Winkler","year":"2021","unstructured":"Winkler C, Armenia J, Jones GN, et al. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. Br J Cancer. 2021;124:951\u201362.","journal-title":"Br J Cancer"},{"key":"215_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012615-044438","volume":"11","author":"D Nassar","year":"2016","unstructured":"Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11:47\u201376.","journal-title":"Annu Rev Pathol"},{"key":"215_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3892\/ijo.2017.4044","volume":"51","author":"Y Yang","year":"2017","unstructured":"Yang Y, Wang G, Zhu D, et al. Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer. Int J Oncol. 2017;51:515\u201324.","journal-title":"Int J Oncol"},{"key":"215_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/s12885-017-3677-7","volume":"17","author":"WJ Aston","year":"2017","unstructured":"Aston WJ, Hope DE, Nowak AK, et al. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017;17:684.","journal-title":"BMC Cancer"},{"key":"215_CR43","first-page":"22","volume":"12","author":"H Minderman","year":"1998","unstructured":"Minderman H, Cao S, Rustman YM. Rational design of irinotecan administration based on preclinical models. Oncology (Williston Park). 1998;12:22\u201330.","journal-title":"Oncology (Williston Park)"},{"key":"215_CR44","unstructured":"ONIVYDE (Irinotecan liposome injection) pharmacology\/toxicology NDA review and evaluation https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/207793Orig1s000PharmR.pdf. Accessed 29 June 2021."},{"key":"215_CR45","unstructured":"Pfizer. Prescribing Information, CAMPTOSAR (irinotecan) injection, for intravenous use. US Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020571s051lbl.pdf. Accessed 29 June 2021."},{"key":"215_CR46","first-page":"727","volume":"20","author":"M Yamamoto","year":"2008","unstructured":"Yamamoto M, Kurita A, Asahara T, et al. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep. 2008;20:727\u201330.","journal-title":"Oncol Rep"},{"key":"215_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s002800000151","volume":"46","author":"A Kurita","year":"2000","unstructured":"Kurita A, Kado S, Kaneda N, et al. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother Pharmacol. 2000;46:211\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"key":"215_CR48","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/jnci\/87.24.1876","volume":"87","author":"N Ikuno","year":"1995","unstructured":"Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst. 1995;87:1876\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"215_CR49","first-page":"3499","volume":"18","author":"W Voigt","year":"1998","unstructured":"Voigt W, Matsui S, Yin MB, et al. Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res. 1998;18:3499\u2013505.","journal-title":"Anticancer Res"},{"key":"215_CR50","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12885-019-5907-7","volume":"19","author":"S Guo","year":"2019","unstructured":"Guo S, Jiang X, Mao B, Li QX. The design, analysis and application of mouse clinical trials in oncology drug development. BMC Cancer. 2019;19:718.","journal-title":"BMC Cancer"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-022-00215-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-022-00215-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-022-00215-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:22:56Z","timestamp":1676553776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-022-00215-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["215"],"URL":"https:\/\/doi.org\/10.1007\/s40487-022-00215-2","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}